CheckMate 77T

Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)

ESMO - European Society for Medical Oncology on LinkedIn: New data

IJMS, Free Full-Text

Dr Amol Akhade on X: Checkmate 77T . Neoadjuvant nivo plus chemo

CheckMate 77T: Perioperative Immunotherapy in Resectable NSCLC

ESMO: Key insights from Phase III trial CheckMate 77T

LUNG CANCER

Dipesh Uprety MD FACP on X: CheckMate-77T #ESMO23 @ESMO

Evolution of Combination Therapies for Clinical Stage IIIA Non

ESMO: Pre- and post-surgical immunotherapy improves outcomes for

CheckMate-77T Trial Meets Primary EFS End Point in Resectable NSCLC

Ahmed Magdy Rabea on LinkedIn: Thank you IASLC for the amazing

Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and

MD Anderson Cancer Center on X: “These findings add to evidence